All In Biotech

Drug Trial Radar · NCT06662539

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 493 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

493

Actual

Start

Dec 9, 2024

Primary completion

Sep 30, 2025

Study completion Mar 7, 2026

Sponsor

Lead sponsor
Zealand PharmaIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.

Conditions

  • Obesity

Interventions

  • PetrelintideDrug

    Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

  • PlaceboDrug

    Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in body weight to Week 28Time frame: From Baseline (Day 1) to Week 28

Locations

32 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Excel Medical Clinical Trials, LLC

    Boca Raton, Florida

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida

  • Century Research LLC

    Miami, Florida

  • Clinical Research Center of Florida

    Pompano Beach, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Great Lakes Clinical Trials LLC dba Flourish Research

    Chicago, Illinois

  • AMR Wichita East

    Wichita, Kansas

  • Alliance For Multispecialty Research, LLC

    Lexington, Kentucky

  • Mercury Street Medical Group, PLLC

    Butte, Montana

  • CHEAR Center LLC

    The Bronx, New York

  • Javara Inc

    Charlotte, North Carolina

  • PharmQuest Life Sciences, LLC

    Greensboro, North Carolina

  • Lucas Research, Inc.

    New Bern, North Carolina

  • AMR Norman

    Norman, Oklahoma

  • Altoona Center for Clinical Research - Research

    Duncansville, Pennsylvania

  • Alliance for Multispecialty Research

    Knoxville, Tennessee

  • Clinical Trials of Texas, LLC., dba Flourish Research

    San Antonio, Texas

  • Manaasas Clinical Research Center

    Manassas, Virginia

  • Krakowskie Centrum MedyczneSp.z o.o

    Krakow, Lesser Poland Voivodeship, Poland

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, Poland

  • FutureMeds Warszawa Centrum

    Warsaw, Masovian Voivodeship, Poland

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji

    Warsaw, Masovian Voivodeship, Poland

  • ETG Warszawa

    Warsaw, Masovian Voivodeship, Poland

  • FutureMeds Targowek

    Warsaw, Masovian Voivodeship, Poland

  • Futuremeds Olsztyn

    Olsztyn, Warmian-Masurian Voivodeship, Poland

  • Institutul National de Endocrinologie C I Parhon

    Bucharest, Romania

  • Institutul Clinic Fundeni

    Bucharest, Romania

  • Fundatia Dr Victor Babes

    Bucharest, Romania

  • Institutul De Pneumoftiziologie Marius Nasta

    Bucharest, Romania

  • Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei Constanta

    Constanța, Romania

  • Top Diabet

    Craiova, Dolj, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.